MAGEA4 and cancer: Preclinical studies also reinforce these outcomes, further substantiating the rationale for MAGE-A4-specific TCR-T cell therapies in challenging cancer types and underscoring the potential of MAGE-A4-specific TCR-T cells in treating challenging cancers (26).